Serena Tharakan1, Brittney Zimmerman2, Meng Ru3, Julia Blanter4, Krystal Cascetta2, Amy Tiersten2. 1. Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA, serena.tharakan@icahn.mssm.edu. 2. Hematology/Oncology Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 3. Department of Population Health and Policy, Icahn School of Medicine at Mount Sinai, New York, New York, USA. 4. Internal Medicine Department, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Abstract
BACKGROUND: The Oncotype DX® (ODX) is a genomic assay that provides clinicians with a prediction of benefit of chemotherapy in node-negative, tamoxifen-treated breast cancer. However, the relationship between ODX recurrence score (RS) and diabetes, a common comorbidity in breast cancer patients, has been inadequately described in the literature. Specifically, the association of diabetes treatment with metformin and RS is inconclusive, with different studies reporting conflicting results. Because diabetes has been associated with higher RS, it has been suggested that management of diabetes with metformin in breast cancer patients may be associated with a lower RS. OBJECTIVES: We studied a large cohort of early-stage, hormone-positive breast cancer patients to determine if there is an association between RS and metformin treatment. METHODS: In this study, we retrospectively examined the medical records of 514 early-stage, hormone-positive breast cancer patients who had oncotype testing performed between 2007 and 2017. Number (%) or median were used to describe the patients' characteristics between groups and were compared by the Kruskal-Wallis test at a significance level of 5%. RESULTS: Of this cohort, 67 (13%) had a diabetes diagnosis at the time of breast cancer diagnosis, including both diabetes mellitus and pre-diabetes. The median RS for non-diabetic patients was 16 and the median RS for diabetic patients was 15. This difference was not significant, nor was there a statistical difference in RS between diabetic patients taking metformin (median RS = 15) and diabetic patients not taking metformin (median RS = 15). These results held true even when controlling for BMI. CONCLUSIONS: We conclude that neither diabetes diagnosis nor metformin use is associated with a difference in oncotype RS in this population of diabetic patients.
BACKGROUND: The Oncotype DX® (ODX) is a genomic assay that provides clinicians with a prediction of benefit of chemotherapy in node-negative, tamoxifen-treated breast cancer. However, the relationship between ODX recurrence score (RS) and diabetes, a common comorbidity in breast cancerpatients, has been inadequately described in the literature. Specifically, the association of diabetes treatment with metformin and RS is inconclusive, with different studies reporting conflicting results. Because diabetes has been associated with higher RS, it has been suggested that management of diabetes with metformin in breast cancerpatients may be associated with a lower RS. OBJECTIVES: We studied a large cohort of early-stage, hormone-positive breast cancerpatients to determine if there is an association between RS and metformin treatment. METHODS: In this study, we retrospectively examined the medical records of 514 early-stage, hormone-positive breast cancerpatients who had oncotype testing performed between 2007 and 2017. Number (%) or median were used to describe the patients' characteristics between groups and were compared by the Kruskal-Wallis test at a significance level of 5%. RESULTS: Of this cohort, 67 (13%) had a diabetes diagnosis at the time of breast cancer diagnosis, including both diabetes mellitus and pre-diabetes. The median RS for non-diabeticpatients was 16 and the median RS for diabeticpatients was 15. This difference was not significant, nor was there a statistical difference in RS between diabeticpatients taking metformin (median RS = 15) and diabeticpatients not taking metformin (median RS = 15). These results held true even when controlling for BMI. CONCLUSIONS: We conclude that neither diabetes diagnosis nor metformin use is associated with a difference in oncotype RS in this population of diabeticpatients.
Authors: Maria Theresa M Redaniel; Mona Jeffreys; Margaret T May; Yoav Ben-Shlomo; Richard M Martin Journal: Cancer Causes Control Date: 2012-09-13 Impact factor: 2.506
Authors: Kimberly S Peairs; Bethany B Barone; Claire F Snyder; Hsin-Chieh Yeh; Kelly B Stein; Rachel L Derr; Frederick L Brancati; Antonio C Wolff Journal: J Clin Oncol Date: 2010-11-29 Impact factor: 44.544
Authors: I Ben Sahra; K Laurent; A Loubat; S Giorgetti-Peraldi; P Colosetti; P Auberger; J F Tanti; Y Le Marchand-Brustel; F Bost Journal: Oncogene Date: 2008-01-21 Impact factor: 9.867
Authors: Sao Jiralerspong; Shana L Palla; Sharon H Giordano; Funda Meric-Bernstam; Cornelia Liedtke; Chad M Barnett; Limin Hsu; Mien-Chie Hung; Gabriel N Hortobagyi; Ana M Gonzalez-Angulo Journal: J Clin Oncol Date: 2009-06-01 Impact factor: 44.544
Authors: Hee Jeong Kim; Hyunwook Kwon; Jong Won Lee; Hwa Jung Kim; Sae Byul Lee; Hee Sung Park; Guiyun Sohn; Yura Lee; Beom Seok Koh; Jong Han Yu; Byung Ho Son; Sei Hyun Ahn Journal: Breast Cancer Res Date: 2015-05-03 Impact factor: 6.466